Personalized Medicine

个性化医学(ISSN 1741-0541)将最近基因组学、遗传学和蛋白质组学的进展转化为临床应用。该杂志为所有参与者提供了一个综合论坛，包括学术和临床研究人员、制药公司、监管机构、医疗管理组织、患者组织和医疗行业的其他组织。个性化医疗通过提供一个专家评论和分析的平台，帮助这些团体塑造医学的未来。该杂志涉及个性化医疗的科学、商业和政策问题，包括新闻和观点，对新生物标志物的最新认识，简明的评论和分析，会议巡回报告和完整的综述文章。提交给个性化医疗的文章必须经过严格的同行审查。讨论的主题包括:分子诊断的进展;生物芯片/微阵列技术;针对特定遗传和免疫靶点的生物疗法或疫苗方法;个性化医疗的成本效益问题;个性化医疗伦理;个性化医疗对医疗保健和制药行业的影响基于药物基因组学、药物基因学和药物蛋白质组学的个性化药物发展的最新概念的影响将遗传分析纳入临床试验方法;诊断与治疗相结合;药物不良反应及安全性预测治疗监测。

Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape the future of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in Personalized Medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles. Articles submitted to Personalized Medicine are subject to rigorous peer review. Topics addressed include: Advances in molecular diagnostics; Biochip/microarray technologies; Biological therapies or vaccine approaches at specific genetic and immunologic targets; Cost-benefit issues for personalized medicine; Ethics in personalized medicine; Impact of personalized medicine on healthcare and the pharmaceutical industry; Impact of the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics and pharmacoproteomics; Incorporation of genetic analysis in clinical trials methodology; Integration of diagnosis with therapy; Prediction of adverse reactions of drugs and drug safety; Treatment monitoring.